scorecardresearch
Add as a preferred source on Google
Sunday, September 20, 2026
Celebrating 9 Years
Support Our Journalism

Support our Journalism

9th Anniversary: Free Tote & Mug

Subscribe
TopicSpinal Muscular Atrophy

Topic: Spinal Muscular Atrophy

Roche patent case: Why SC refused to halt Natco’s generic spinal muscular atrophy drug Risdiplam

Roche had approached Delhi High Court, accusing Natco of violating its Indian patent, before going to the Supreme Court with its petition.

India approves Zolgensma, one of world’s costliest drugs. Why it’s sparked hope, but also concern

Zolgensma is the only drug that promises a cure for Spinal Muscular Atrophy, provided it is administered to affected children before the symptoms appear.

New hope for rare disease patients: Rs 900-cr govt project to get high-value drugs at lower rates in works

India has 8.4 to 19 crore rare disease patients, according to health ministry estimates. But current beneficiaries in most cases are kids or those who need relatively less expensive drugs.

On Camera

Trump threatened to redraw the map. Greenland deal shows the limits of his disruption

The bargain was never sovereignty in exchange for security. It was extensive American military freedom inside continuing Danish sovereignty.

Tiruppur’s success runs on cheap cotton. India needs to ask who pays for it

Repeated changes in cotton import duty have prioritised textile competitiveness when mills face high input costs. But policy can also put pressure on farmgate prices.

At Tejas trainer handover, Rajnath warns delays can lead to ‘technology obsoletion’

HAL finally closes 2010 Tejas order but work remains on Mk1A and the first delivery is unlikely before IAF chief retires end of October.

Bangladesh isn’t a mirror image of Pakistan. Hyphenating them undermines India’s strategic interests

India is caught in a trap of its own making. While BJP may find it convenient to play on insecurities, it gives Pakistan and Bangladesh leverage.